Hunan Jiudian shareholders approve capital and bylaw changes

Hunan Jiudian Pharmaceutical held its first extraordinary general meeting of shareholders for 2025 on September 9, 2025. The meeting, attended by representatives of 47.8586% of total voting shares, adopted two key proposals.

Proposal 1.00, regarding the change of use of raised funds, was approved with 99.7695% of votes in favor. Smaller investors also largely supported this, with 87.9818% in favor.

Proposal 2.00, which required a two-thirds majority, focused on altering the registered capital and amending the company's articles of association. This proposal passed with 99.7846% of votes in favor. Both proposals were deemed legally valid by Hunan Qiyuan Law Firm.